English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/185557
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Identification of NEK3 and MOK as novel targets for lithium

AuthorsBravo, Ana; de Lucio, H.; Sánchez-Murcia, Pedro A. ; Jiménez-Ruiz, Antonio; Petrone, P. M.; Gago, Federico; Cortés Cabrera, Álvaro
KeywordsBipolar disorder, GSK3B, Lithium, MOK, NEK3
Axonal growth
Issue Date2019
PublisherJohn Wiley & Sons
CitationChemical Biology and Drug Design 93: 965-969 (2019)
AbstractLithium ion, commonly used as the carbonate salt in the treatment of bipolar disorders, has been identified as an inhibitor of several kinases, including Glycogen Synthase Kinase-3β, for almost 20 years. However, both the exact mechanism of enzymatic inhibition and its apparent specificity for certain metalloenzymes are still a matter of debate. A data-driven hypothesis is presented that accounts for the specificity profile of kinase inhibition by lithium in terms of the presence of a unique protein environment in the magnesium-binding site. This hypothesis has been validated by the discovery of two novel potential targets for lithium, namely NEK3 and MOK, which are related to neuronal function.
Publisher version (URL)http://dx.doi.org/10.1111/cbdd.13487
Identifiersdoi: 10.1111/cbdd.13487
issn: 1747-0277
e-issn: 1747-0285
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.